News|Articles|September 2, 2026

Viral Vector Quality: No Estimates. Only Evidence

Listen

0:00 / 0:00

Key Takeaways

Viral titer alone can mask clinically relevant differences in empty/full ratios, fragmented genomes, and higher-order aggregates that influence potency, safety, and regulatory defensibility.
Charge detection mass spectrometry provides direct capsid mass distributions, enabling streamlined characterization and relative quantitation of AAV subpopulations across development and QC workflows.
Alignment with USP AAV8 reference standards supports method benchmarking, comparability claims, and more reproducible interpretation of capsid occupancy profiles.
SEC-MALS-UV-dRI offers quantitative aggregation and heterogeneity readouts, improving confidence in purity assessments and lot-to-lot consistency evaluations.
RT-MALS enables in-line/at-line tracking of chromatographic enrichment, facilitating real-time monitoring and tighter control of manufacturing performance.

Move beyond inferred measurements and gain direct insight into the viral vector quality attributes that drive efficacy, safety, and manufacturing confidence.

AAV quality depends on more than viral titer alone. Capsid occupancy, aggregation, genome integrity, and product heterogeneity all impact therapeutic performance and regulatory readiness. Explore how CDMS and MALS help scientists generate direct, defensible evidence to support development, manufacturing, and QC decisions.

Characterizing AAVs

Xevo CDMS Characterization of Viruses and Viral-based Therapeutics

Streamlined Characterization of Recombinant AAVs via Charge Detection Mass Spectrometry: Insights from the USP AAV8 Reference Standards

Characterization with Relative Quantitation of Adeno-Associated Viruses (AAVs) using Xevo Charge Detection Mass Spectrometry (CDMS)

Quantifying quality attributes of AAV gene therapy vectors by SEC-MALS-UV-dRI

Real-time monitoring and control of AAV chromatographic enrichment by RT-MALS

Newsletter

Stay at the forefront of biopharmaceutical innovation. Subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.